CAS 3027172-23-9

pan-KRAS-IN-5

Description:

Pan-KRAS-IN-5 is a small molecule inhibitor designed to target KRAS mutations, particularly those associated with various cancers. It is part of a class of compounds aimed at disrupting the oncogenic signaling pathways activated by mutant KRAS proteins. The compound exhibits specificity for KRAS G12C mutations, which are prevalent in several malignancies, including lung and colorectal cancers. Its mechanism of action typically involves binding to the mutant KRAS protein, thereby inhibiting its activity and downstream signaling, which can lead to reduced tumor growth and proliferation. Pan-KRAS-IN-5 is characterized by its potential to overcome resistance mechanisms often seen with other targeted therapies. In preclinical studies, it has shown promise in reducing tumor burden and improving survival rates in models of KRAS-driven cancers. As with many investigational drugs, ongoing research is focused on optimizing its pharmacokinetic properties, assessing its safety profile, and determining its efficacy in clinical settings.

Formula: C₃₁H₃₆FN₄O₂·I

Synonyms:

• pan-KRAS-IN-5
• Quinolinium, 2-[(1E)-2-[7-(diethylamino)-2-oxo-2H-1-benzopyran-3-yl]ethenyl]-6-fluoro-1-methyl-7-[[2-(1-pyrrolidinyl)ethyl]amino]-, iodide (1:1)

pan-KRAS-IN-5

CAS: 3027172-23-9

Pan-KRAS-IN-5 (compound 15a) is a pan-KRAS translation inhibitor targeting 5′-UTR RNA G-quadruplexes (rG4s). It induces cell cycle arrest and promotes apoptosis in KRAS-driven cancer cells [1].

Formula: C₃₁H₃₆FIN₄O₂

Color and Shape: Solid

Molecular weight: 642.55

Ref: TM-T87101